Synthesis Bone Mineral (SBM) for Osteoporosis Therapy: Part 1 - Prevention of Bone Loss from Mineral Deficiency


Article Preview

Osteoporosis is a ‘silent’ disease characterized by thinning cortical bone and disorganized trabecular architecture causing bone fragility leading to fracture. Osteoporosis results when the rate of bone resorption far exceeds the rate of bone formation. Current pharmaceutical interventions (estrogen therapy, bisphosphonate-based drugs) focus on inhibiting bone resorption. However, some of these therapies have serious side effects (e.g., cancer risk from estrogen therapy; osteonecrosis of the jaw and delayed fracture healing from bisphosphonate-based drugs). The long term objective of the study was to develop a novel material for potential osteoporosis therapy, prevention and fracture repair. This novel material MZF-CaP or synthetic bone mineral, SBM) incorporates Mg, Zn and F ions in a calcium phosphate matrix. Separately, magnesium (Mg), zinc (Zn) and fluoride (F) ions have been associated with biomineralization and osteoporosis therapy in human and in animals. MZF-CaP or SBM was prepared by a modified hydrolysis method previously described and characterized using x-ray diffraction, FT-IR spectroscopy, inductive coupled plasma and dissolution in acidic buffer. Separately, male and female Sprague-Dawley rats were randomly assigned to the following groups depending on the diet: GA: normal on basic diets; GB: on mineral deficient diets (md); GC: on md + Mg-CaP; GD: on md + Zn-CaP; GE: md+F-CaP; and GF: md+MZF-CaP. The rats were sacrificed after 3 months and the femur bones separated, cleaned of extraneous soft tissues and stored until needed for analyses. Femur bones were analyzed using microradiography (Faxitron), scanning electron microscopy (SEM) and microCT. Results: SEM, Faxitron and microCT analyses showed thinning of cortical bone and disorganized trabecular bone architecture for osteoporotic rats on mineral deficient diet (GB) and prevention of bone loss in rats receiving the supplemented diets (GC,GD,GE,GF). Conclusion: These results indicate that the novel material, MZF-CaP or SBM had a potential for osteoporosis therapy and prevention. Studies to demonstrate the use of SBM in reversing (recovering) bone loss are in progress.



Key Engineering Materials (Volumes 361-363)

Main Theme:

Edited by:

Guy Daculsi and Pierre Layrolle




R. Z. LeGeros et al., "Synthesis Bone Mineral (SBM) for Osteoporosis Therapy: Part 1 - Prevention of Bone Loss from Mineral Deficiency", Key Engineering Materials, Vols. 361-363, pp. 43-46, 2008

Online since:

November 2007




[1] Interational Osteoporosis Foundation (2007). (http/www. iofbonehealth. org/health).

[2] Merrill RM, Weed DL, Feuer EJ (1997). Cancer Epid Biomarkers Prev 6: 763-771.

[3] Parfitt AM (1994). J Cell Bichem 55: 273-286.

[4] Rossouw JE, Anderson GL, Prentice RL, et al (2002). JAMA 288 : 321-333.

[5] Ruggiero ST, Mehrotra B, Toosenbert TJ (2004). J Oral Maxilllofac Surg 62: 527-534.

[6] NIBIB/NIH Research Grant no. 1RO1 EB 003070. Patent No. WO 2005/032466 A3.

[7] Pak CYC, Sakhaee K, Bell NH et al (1996). J Bone Miner Res 11: 160-168.

[8] Rude K, Gruber HE (2004). J Nutr Biochem 15: 710-715.

[9] Eberle J, Schmidmayer S, Erben RG et al (1999). J Trace elements Med Biol 13: 21-26.

[10] LeGeros RZ, LeGeros JP, Trautz OR et al (1971). Adv X-ray Anal 14: 57-66.

[11] LeGeros RZ (1981). Prog Crystal Growth Charact 4: 1-45.

[12] Otsuka M, Oshinbe A, Ito A, et al (2006). Key Engineer Mater 254-256: 343-346.

[13] Tokudome Y, Otsuka M, Ito A, LeGeros RZ (2006). IADR abstract no. 1138.

[14] Mohan S, Baylink DJ (1996). In: Principles of Bone Biology. Ch 80. Academic Press: New York, p.11111124.